Keyword: AstraZeneca

AstraZeneca's Fasenra hasn't had an easy time challenging GlaxoSmithKline’s Nucala. And doing so just got harder close to home.

With Brexit looming, AstraZeneca has taken up three lines of defense to forestall potential supply disruptions.

A film based on the true story of a leukemia patient smuggling Indian generics has led Beijing to reiterate its intention to cut cancer drug prices.

At ADA, an AstraZeneca executive said he's "very optimistic" about the company's cardiovascular outcomes study for Farxiga.

AstraZeneca and Merck are eyeing a $1 billion boost for Lynparza, thanks to a trial win for women who have just been diagnosed with ovarian cancer.

Imbruvica is the only treatment for Waldenström's macroglobulinemia patients. But before competition hits, its makers are pushing for a wider market.

In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.

Tagrisso will enjoy quick uptake in a couple of new indications to win 95% of EGFR-mutated NSCLC patients by 2020, a bullish analyst figures.

Patients on Trulicity were more likely to continue therapy after a year than those on rival meds, according to data presented at ADA.

Invokana carries a warning for amputation risks, but an analysis found the drug lowered heart failure hospitalizations without increasing those risks.